Melinta Therapeutics to buy Tetraphase for $39m

Melinta Therapeutics has agreed to acquire Tetraphase Pharmaceuticals Inc, a biopharmaceutical company, for $39 million in cash.

8 June 2020•6 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Healthcare M&A Deals Briefs